Sunovion Pharmaceuticals Inc.

Marlborough-based pharmaceutical company Sumitomo Pharma America, a U.S. subsidiary of Japanese parent company Sumitomo Pharma, is set to lay off 53 employees, as the company continues to reduce its workforce.

Sunovion Pharmaceuticals and two other subsidiaries of the soon-to-be-combined Marlborough drugmaker Sumitomo Pharma America will lay off 223 workers as their Japanese parent company restructures the entire organization in America.

Marlborough company Sunovion Pharmaceuticals Inc. has begun its in-human clinical trials for a drug to treat generalized anxiety disorder.

Sunovion Pharmaceuticals of Marlborough will lay off 360 of its 1,200 employees, effective Jan. 13.

Eight women from around Central Massachusetts have earned the honor this year.

Marlborough company Sunovion Pharmaceuticals announced on Thursday it granted exclusive commercial license rights in Europe to Portugese company Bial for Sunovion's KYNMOBI, an under-the-tongue drug treating OFF episodes in patients with Parkinson’s disease.

Marlborough pharmaceutical company Sunovion announced on Monday the commercial launch of KYNMOBI, a drug aimed at treating OFF episodes in patients with Parkinson’s disease.

Marlborough pharmaceutical firm Sunovion has announced promising results from a study for a bipolar disorder drug, sending development to a third phase of testing.

Sunovion, a Marlborough pharmaceutical company, has won Canadian regulatory approval for a drug treating episodes in those with Parkinson's disease.

Marlborough pharmaceutical firm Sunovion said Thursday it has received federal approval for the first drug for Parkinson's disease which dissolves under the tongue.